MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors by Honorat, Mylène et al.
SAGE-HindawiAccess to Research
International Journal of Breast Cancer
Volume 2011, Article ID 807380, 6 pages
doi:10.4061/2011/807380
Research Article
MRP8/ABCC11ExpressionIsRegulated byDexamethasonein
BreastCancerCells and IsAssociatedtoProgesterone Receptor
StatusinBreastTumors
Myl` ene Honorat,1,2,3 Aur´ elia Mesnier,1,2,3 Julie Vendrell,1,2,3 Attilio Di Pietro,4 Val´ erie Lin,5
CharlesDumontet,1,2,3 Pascale Cohen,1,2,3 andL´ ea Payen1,2,3,6,7
1Universit´ e de Lyon, Lyon1, Lyon 69008, France
2Inserm, U590, Lyon 69008, France
3Centre L´ eon B´ erard, FNCLCC, Lyon 69008, France
4Equipe Labellis´ ee Ligue 2009, Institut de Biologie et Chimie des Prot´ eines FR 3302, BM2SI, UMR 5086/Universit´ eL y o n1 ,
IFR128 BioSciences Gerland, 69367 Lyon Cedex 07, France
5School of Biological Sciences, Nanyang Technological University, Singapore 637616
6Laboratoire de Toxicologie, Facult´ e de Pharmacie, ISPB, Universit´ e de Lyon, Lyon 69008, France
7Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de biochimie, 69495 Pierre-B´ enite, France
Correspondence should be addressed to L´ ea Payen, lea.payen@recherche.univ-lyon1.fr
Received 2 July 2010; Revised 2 December 2010; Accepted 20 December 2010
Academic Editor: Sarah E. Pinder
Copyright © 2011 Myl` ene Honorat et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The ATP-binding cassette multidrug resistance protein 8 (MRP8/ABCC11) mediates the excretion of anticancer drugs. ABCC11
mRNA andprotein levels were enhanced by DEX (dexamethasone)andby PROG(progesterone) inMCF7 (progesterone receptor-
(PR-) positive) but not in MDA-MB-231 (PR-negative) breast cancer cells. This suggested a PR-signaling pathway involvement
in ABCC11 regulation. Nevertheless, pregnenolone-16α-carbonitrile (GR antagonist) and clotrimazole strongly and moderately
decreased ABCC11 expression levels in Glucocortocoid Receptor-(GR-) and Pregnane X Receptor (PXR)-positive MCF7 cells but
not in MDA-MB-231 cells (GR- and PXR-positive). Thus, GR-signaling pathway involvement could not be excluded in ABCC11
regulation in MCF7 cells. Furthermore, ABCC11 levels were positively correlated with the PR status of postmenopausal patient
breast tumors from two independent cohorts. Thus, in the subclass of breast tumors (Estrogen Receptor-(ER-) negative/PR-
positive), the elevated expression level of ABCC11 may alter the sensitivity to ABCC11 anticancer substrates, especially under
treatment combinations with DEX.
1.Introduction
Among the members of the ATP-binding cassette (ABC)
transporter superfamily, MRP8/ABCC11 (MultiDrug Resis-
tance Protein 8) is a full-length ABC transporter associated
with resistance to methotrexate and ﬂuoropyrimidines, two
classes of agents widely used for breast cancer treatments
[1, 2]. ABCC11 transcripts were overexpressed in estro-
gen receptor-(ER-) positive breast cancers [3]. As apically
expressed, ABCC11 protein is likely to play a signiﬁcant
role in absorption, distribution and elimination of its
substrates [4]. ABCC11-mediated transport of anticancer
drugs, combined with its expression levels in a hormonally-
regulatedbreasttissue,suggestthatthepumpexpression may
beregulatedbyxenobiotics.Dexamethasone (DEX),apotent
anti-inﬂammatory factor, has already found very broad
clinical applications for treatment of diverse conditions,
ranging from associated diseases and asthma to cancer
therapy [5]. DEX is a well-known activator of numerous
signaltransductionandmoleculargene-regulationpathways.
It frequently involves nuclear receptors, including pregnane
X receptor (PXR), glucocorticoid receptor (GR) and pro-
gesterone receptor (PR) [6]. The aim of this work was to
determine whether a DEX treatment may lead to any change2 International Journal of Breast Cancer
in the expression level of ABCC11 protein in MCF7 breast
cancer cells, an endocrine-related cell model.
2.Materialsand Methods
2.1. Chemicals and Cell Lines. DEX, PROG, clotrimazole
and pregnenolone 16α-carbonitrile (PCN) were purchased
from Sigma Aldrich (France). TRIZol RNA extraction
kit, murine moloney leukemia virus reverse transcriptase
(MMLV-RT), Taq DNA polymerase, complete high-glucose
Dulbecco’smodiﬁed Eagle’s medium (DMEM), L-glutamine
and penicillin-streptomycin were manufactured by Gibco
(France), and fetal bovine sera by PAN Biotech GmbH
(Aidenbach, Germany). To avoid interference by steroids
present in classical media, cell lines were ﬁrst purged for 4
days in DMEM without phenol red, supplemented with 3%
steroid-depleted, dextran-coated and charcoal-treated, fetal
calf serum (DCC medium). The culture media were then
used in either presence or absence of various molecules as
described in Honorat et al. (2008)[3]. We used (PR-positive,
ER-positive, GR-positive and PXR-positive) MCF7 and (PR-
negative, ER-negative, GR-positive and PXR-positive) MDA-
MB231 cells stably transfected with both empty pBK-CMV
and pSG5-plasmids (called pSG5-MDA-MB231). The last
cell line is derived from MDA-MB-231 cells and displays a
similar phenotype about PR and ER status.
2.2.BreastTumorSamples. Allexperimentalprocedureswere
performed in compliance with French laws and regulations
and were approved by the Ethics Committee. Sixty primary
t u m o r sf r o mp a t i e n t s ,w i t hn ot h e r a p yp r i o rt os u r g e r y ,w e r e
collected from postmenopausal women at the Pathology
Department of Val d’Aurelle Cancer Center (Montpellier,
France) [7]. The malignancy of inﬁltrating carcinomas was
scored according to the histological prognostic system of
Scarﬀ-Bloom-Richardson [8]. The ER-positive status was
determined at the protein level by a radio-ligand binding
assay (with a cut-oﬀ level for positivity set at 10fmol/mg of
proteinaccordingtotheWHOtypingsystem)andconﬁrmed
by an ER quantitative RT-PCR assay. The PR status was
measured at the protein levelby a binding assay as previously
described [9].
In parallel, normalized data from an independent cohort
of 245 breast tumors (Bittner Breast’s study) were extracted
from the GEO website. ABCC11 expression levels were
analyzed in breast tumors whose PR and ER clinical status
were indicated (mostly deﬁned by immunohistochemistry
(IHC)).
2.3. Quantitative Real-Time RT-PCR (QRT-PCR). Total
mRNA extraction and QRT-PCR were performed as
described in Honorat et al. (2008) [3].
2.4. Immunoblotting and Quantiﬁcation. Protein expression
was analysed by immunoblotting analysis as previously
described in [3]. Densitometry was performed using the
ImageJ software.
2.5. Statistical Analysis. Data were analyzed for statistical
signiﬁcance using either Mann Whitney’s test or Student’s
t-test. Diﬀerences with P-values <. 05 were considered as
statistically signiﬁcant.
3.Resultsand Discussion
The expression levels of ABC transporters are highly regu-
lated by xenobiotics, including estrogens, PROG and DEX
[2]. These regulations may control the availability of many
substrates, including anticancer drugs, by either increasing
or decreasing their elimination from cells. They can inﬂu-
ence the cell sensitivity to their substrates. Consequently,
we characterized DEX regulation pathways of ABCC11
in PR-positive MCF7 cells. For the ﬁrst time, ABCC11
expression levels were shown to be increased in a time-
dependent manner by 5μMD E X ,w i t hat r e n dt o w a r d s
higher ABCC11 levels after a 24-h exposure, and a maximal
andsigniﬁcantinductionafter48–72h(Figure 1(a))inDEX-
treated cells compared to vehicle-treated cells. Furthermore,
DEX strongly enhanced ABCC11 mRNA levels in a dose-
dependent manner (Figure 1(b)). ABCC11 mRNA amounts
were slightly upregulated after 48-h exposure to a very low
DEX concentration (0.001μM, Figure 1(b)); higher concen-
trations(0.05μM) were howeverrequiredtoreach a maximal
and signiﬁcant induction. The molecular mechanisms of
ABCC11 regulation were further explored by demonstrating
that, in MCF7 cells, the physiological PR ligand PROG
regulated ABCC11 expression in the same way as DEX, while
DEX and PROG did not modify ABCC11 expression in PR-
negative pSG5-MDA-MB-231 breast cells. PROG at 15μM
induced ABCC11 gene expression in MCF7 cells, whereas
no regulation was observed in PR-negative pSG5-MDA-MB-
231 cells (Figure 2(a)). In agreement, by immunoblotting,
both DEX and PROG increased ABCC11 protein expression,
by at least 2-fold, in comparison to the vehicle control
(Figure 2(b)). Additional bands, observed below 116kDa,
were probably due to proteolytic degradation of ABCC11
a sd e s c r i b e db yB o r t f e l de ta l .[ 4]. DEX can activate PR-
signaling pathways[6,10].SinceABCC11regulationby DEX
and PROG only occurred in PR-positive MCF7 cells and not
in PR-negative pSG5-MDA-MB-231 cells, we hypothesized
that the eﬀects of DEX and PROG on ABCC11 expres-
sion could be partially related to PR-signaling pathways.
Interestingly, by in silico analysis of the human ABCC11
promoter region (−5000, chr16: 38685979-), we found two
progesterone-response elements (PRE).
Based upon the observation that ABCC11 expression
levels were upregulated by DEX, we next evaluated whether
ABCC11 expression was also regulated by other ligands of
GR and PXR. PCN is known as a weak hPXR activator and
as a potential GR antagonist [11–13]. PCN at 5μMa n d
10μM strongly decreased ABCC11 expression in MCF7 cells
and had no eﬀect in MDA-MB-231 cells (Figure 3). Though
MDA-MB-231 cells strongly expressed GR, no eﬀects of
either DEX or PROG were observed on ABCC11 expression
(Figure 2(a)). The default of PCN, DEX and PROG eﬀects
via GR in MDA-MB-231 cells may be directly relatedInternational Journal of Breast Cancer 3
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Figure 1: DEX time-course and dose-dependent eﬀects on ABCC11 mRNA expression. MCF7 cells were exposed to 5μMD E Xf o r4t o7 2h
(a) or to DEX concentrations ranging from 0.001 to 5μM (b). Fold change of mRNA levels of ABCC11 was determined by QRT-PCR. The
QRT-PCR values indicated below are means ± S.D. of at least 4 independent experiments; y is a logarithmic scale. ∗P<. 05; student’s t-test.
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Figure 2: Alterations of ABCC11 mRNA and protein level by DEX and PROG. (a) Cells were exposed to either 5μMD E Xo r1 5μMP R O G
for 72h. Fold change of mRNA levels of ABCC11 was determined by QRT-PCR. The QRT-PCR values indicated below are means ± S.D. of
4 independent experiments; y is a logarithmic scale. ∗P<. 05; student’s t-test. (b) Crude membrane fractions (150μg) were prepared from
cells exposed to either vehicle, 5μMD E Xo r1 5μMP R O Gf o r7 2h .
to the “cellular context”. Indeed, GR may regulate gene
transcription by various mechanisms: synergistic activity
where transcription factors bound at other DNA sites
cooperate with ligand-activated GR bound to a consensus
glucocorticoid-response element (GRE); interference with
the actions of other transcription factors (e.g., AP-1 and
NF-κB) through protein-protein interactions, which does
not require GR binding to DNA; and either repression
or stimulation via requisite interactions of GR with other
transcription factors all bound at so-called composite GREs
[14–16]. DEX had been demonstrated to increase c-fms
transcript and protein levels in breast cells (SKBR3 and
BT20), but not in others (MCF7) [17]. Consequently, in
MCF7 cells, the involvement ofGR-signaling pathways could
not be completely excludedand is somehow suggested by the
GRE motif revealed in the in silico analysis of the human
ABCC11 promoter region (−5000) using the Genomatix
software.
Finally, we used clotrimazole, a powerful human PXR
ligand toexplorePXRsignaling pathways. Clotrimazoleat5–
10μM did not producea major eﬀecton ABCC11 expression
in MCF7 cells and had no eﬀect on ABCC11 expression in
MDA-MB231 cells (Figure 3). In addition, little is known
about PROG direct interaction with PXR-signaling pathway,4 International Journal of Breast Cancer
Table 1: Relationships between ABCC11 mRNA expression, PR-status and ER-status in breast tumors from postmenopausal patients.
Subgroup n Median Range
(min-max)
Ratio
(subgroup 2 median/
subgroup 1 median)
P
￿
Present study†§
PR− 26 2,22 (0,1–289) 5,79 .014
PR+ 34 12,86 (0,6–354)
ER−/PR− 23 1,50 (0,1–177) 11,21 .009
ER−/PR+ 12 16,82 (0,8–354)
ER+/PR− 3 33,37 (8,9–289) 0,36 .181
ER+/PR+ 22 11,99 (0,6–286)
Bittner’s study
PR− 116 86,50 (2,4–12494) 2,47 .003
PR+ 129 213,50 (1,7–11933)
ER−/PR− 83 53,80 (2,4–12494) 9,80 .075
ER−/PR+ 3 527,10 (199,8–1866)
ER+/PR− 33 225,10 (4,6–4950) 0,87 .871
ER+/PR+ 125 196,00 (1,7–11933)
Present study:n = 60 tumors.
Bittner’s study:n = 245; from normalized data published on GEO website GSE2109-ABCC11(224146 s at).
†ABCC11 QRT-PCR expression levels.
§PR and ER statuswere measured at the protein level by binding assay.
‡P-values were considered to be statisticallysigniﬁcant if P<. 05 (Mann Whitney’s test).
and PCN and DEX were relatively weak activators of human
PXR as compared to clotrimazole. Although PCN weakly
decreased ABCC11 expression in PXR-positive MCF7 cells,
noregulatoryeﬀectwasobservedinPXR-positiveMDA-MB-
231 cells. We may then suggest that PXR-signaling pathway
was likely not directly involved in ABCC11 regulation by
DEX and PROG. The overall results suggest that regulation
of ABCC11expression by PROG and DEX is at least partially
linked to PR signaling pathways.
Currently, the PR-positive status of breast tumors is
recognized as an important indicator of the likelihood of
response to endocrine agents [18]. Approximately two-
thirds of breast cancers express the estrogen receptor alpha
(ERα), some of them being PR-negative. PR absence sig-
niﬁcantly correlated with a less diﬀerentiated phenotype of
breast tumors [18]. Based upon our in vitro observation,
we evaluated whether there was any correlation between
ABCC11 expression and PR status in 60 breast cancers from
postmenopausal women (fully described [3, 7]). In this local
cohort of patient, the PR and ER status were evaluated
at the protein level by binding assays [7]. Signiﬁcantly
higher ABCC11 mRNA levels were observed in PR-positive
tumors than in PR-negative samples (ABCC11 levels were
approximately 6-fold higher in the PR-positive groups than
in the PR-negative groups; P = .014 Mann Withney’s test
(Table 1)). To conﬁrm those observations, we extracted and
analysed the normalized data of ABCC11 expression level
of 245 breast tumors from an independent cohort (Bit-
tner Breast’s study from the GEO website). We only retained
breast tumors whose PR and ER clinical status, mostly
deﬁned by immunohistochemistry (IHC), were indicated.
We validated a positive association between PR status and
ABCC11 expression levels in this larger cohort of breast
tumors (Table 1; P = .003).
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Figure 3: Alteration of ABCC11 mRNA level by clotrimazole
and PCN. MCF7 cells were treated for 72h with 15μMP R O G ,
5–10μMc l o t r i m a z o l eo r5 – 1 0 μMP C N .F o l dc h a n g eo fm R N A
levels of ABCC11 was determined by QRT-PCR. The QRT-PCR
values indicated below are means ± SD. at least three independent
experiments. ∗P<. 05; student’s t-test.
We previously observed a high signiﬁcant ABCC11
mRNA levels in breast cancer tumors possessing high levels
ofERαcomparedto those having lowlevels[3].We validated
a positive association between ABCC11 expression level and
ER status in Bittner’s breast cohort (n = 159; ER-negative
tumors; n = 86; ER-positive tumors; P = .0004 Mann
Whitney’s test).Wedecidedto carry outsubclassesoftumors
according their ER status. In our tumor cohort, the ABCC11
mRNA level diﬀerence between breast tumors according toInternational Journal of Breast Cancer 5
PR-status was only found signiﬁcant in patients with ER-
negative status. ABCC11 expression levels were approxi-
mately 11-fold higher in the ER−/PR+ subgroup than in
ER−/PR− patient subgroup (P = .009; Mann Whitney’s
test). While not reaching signiﬁcant diﬀerence (P = .076),
a tendency had been found in the ER-negative subgroup of
Bittner’s Breast cohort. The median ratio between PR−/PR+
was approximately 9-fold (Table 1). This might be directly
related to the tiny number of ER−/PR+ tumors (n = 3).
Since this repartition is representative of clinical situation
(ER-positive status is frequently associated with PR-positive
status), this observation fully justify the limited number of
ER−/PR+ tumors in studied clinical cohorts.
By contrast, in both cohorts, tumors with ER-positive
status did not show any correlation between ABCC11
expression levels and PR status (Table 1). This suggests
that in ER-positive breast tumors, the ER status is mainly
associated in ABCC11 mRNA levels, while in ER-negative
breast tumors ABCC11 expression levels are associated with
PR-status.
4.Conclusion
Currently, breast chemotherapies frequently include 5-FU
(metabolized in cells to 5FdUMP, which is an ABCC11
substrate). Interestingly, Park et al. studied the relationship
betweenABCtransportergeneexpressionandchemotherapy
responsiveness inearlybreast cancerpatientswhounderwent
sequential weekly paclitaxel/FEC (5-FU, epirubicin and
cyclophosphamide)neoadjuvanttherapy.SeveralABCtrans-
porters including ABCC5 and ABCC11 showed signiﬁcant
increased expression in the residual disease [19]. Taken
altogether, the association between PR and ABCC11, in
a subgroup of breast tumors with low expression of ER,
highlightedhowABCC11mightconstituteaputativemarker
of 5-FU anticancer resistance.
Furthermore, by altering ABCC11 expression levels,
DEX, an adjuvant anticancer drug, may signiﬁcantly con-
tribute to chemo-resistance mechanisms to ABCC11 sub-
strates. High expression levels of ABCC11 in PR-positive
breast tumors with low expression of ER alpha may
contribute to a decreased sensitivity to chemotherapeutic
combinations containing 5-FU. Future work is needed to
investigate this point.
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